Evidence map›Paper›PMID 42713476›Full record

ArticleCureus2026

Severe Dupilumab-Associated Psoriasis Flare After Switching From Ustekinumab for Biopsy-Proven Eczematous Dermatitis: A Case Report.

Doaa AlAwadhi, Reem AlQusaimi, Fawziah AlRujaib, Fahad AlSharhan, Abdullah AlShatti, Bader Alflaij, Dana Alobaid, Suad Alassaf, Fatemah Abdulrahman, Munirah F AlEnezi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Doaa AlAwadhiDermatology, Abdulkareem AlSaeed Dermatology Center, Kuwait City, KWT.
Reem AlQusaimiDermatology, Abdulkareem AlSaeed Dermatology Center, Kuwait City, KWT.
Fawziah AlRujaibDermatology, Abdulkareem AlSaeed Dermatology Center, Kuwait City, KWT.
Fahad AlSharhanDermatology, Abdulkareem AlSaeed Dermatology Center, Kuwait City, KWT.
Abdullah AlShattiMedicine, Sheikh Jaber Al-Ahmad Al-Sabah Hospital, Kuwait City, KWT.
Bader AlflaijMedicine, Sheikh Jaber Al-Ahmad Al-Sabah Hospital, Kuwait City, KWT.
Dana AlobaidMedicine, Kuwait University, Kuwait City, KWT.
Suad AlassafMedicine, Mirza Hassan Al Ahqaqee Clinic, Kuwait City, KWT.
Fatemah AbdulrahmanDermatology, Mussaaed Al-Saleh Health Center, Kuwait City, KWT.
Munirah F AlEneziDermatology, Al Jahra Hospital, Kuwait City, KWT.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dupilumab is an effective treatment for moderate-to-severe atopic dermatitis but has been increasingly associated with paradoxical psoriasis and psoriasiform manifestations. Severe exacerbation of pre-existing psoriasis following dupilumab therapy remains uncommon and presents a therapeutic challenge. We report a patient with well-controlled chronic plaque psoriasis who developed eczematous dermatitis with histopathological findings consistent with the diagnosis. Although dupilumab effectively controlled the eczema, the patient subsequently developed a severe generalized psoriasis flare after switching from ustekinumab. Clinical improvement was achieved after restarting ustekinumab and methotrexate. This case highlights the potential for dupilumab to trigger severe paradoxical psoriasis in patients with pre-existing psoriatic disease. Clinicians should remain vigilant when prescribing dupilumab in this population, and early recognition with prompt modification of therapy may lead to favorable clinical outcomes.

Indexed as

atopic dermatitisbiologic therapydupilumabparadoxical psoriasisustekinumab

Identifiers

PMID42713476
PMCPMC13552342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.